Table 3.
Landmark circulating tumor DNA (ctDNA) by treatment arm and disease stage for patients with available landmark ctDNA results (N = 38)
| Variable | Overall (N = 45) | Landmark ctDNA | p-value | ||
|---|---|---|---|---|---|
| Yes (N = 13) | No (N = 25) | ||||
| Arm Assigned | A: Nivolumab | 15 (33.3%) | 6 (46.2%) | 7 (28.0%) | 0.482 |
| B: Capecitabine | 15 (33.3%) | 4 (30.8%) | 8 (32.0%) | ||
| C: Combination | 15 (33.3%) | 3 (23.1%) | 10 (40.0%) | ||
| Clinical Staging | IA | 2 (4.4%) | 1 (7.7%) | 1 (4.0%) | 0.007 |
| IB | 1 (2.2%) | 0 (0%) | 1 (4.0%) | ||
| IIA | 17 (37.8%) | 1 (7.7%) | 13 (52.0%) | ||
| IIB | 7 (15.6%) | 5 (38.5%) | 2 (8.0%) | ||
| IIIA | 13 (28.9%) | 6 (46.2%) | 5 (20.0%) | ||
| IIIB | 5 (11.1%) | 0 (0%) | 3 (12.0%) | ||
| Pathological Staging | IA | 10 (22.2%) | 0 (0%) | 10 (40.0%) | 0.001 |
| IB | 3 (6.7%) | 0 (0%) | 2 (8.0%) | ||
| IIA | 14 (31.1%) | 3 (23.1%) | 7 (28.0%) | ||
| IIB | 6 (13.3%) | 3 (23.1%) | 3 (12.0%) | ||
| IIIA | 6 (13.3%) | 2 (15.4%) | 3 (12.0%) | ||
| IIIC | 6 (13.3%) | 5 (38.5%) | 0 (0%) | ||
All p-values were calculated from the two-sided Fisher’s exact test without adjustment.